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Abstract: Detecting the patterns of DNA sequence variants across the human genome is a crucial step for unraveling the 
genetic basis of complex human diseases. The human HapMap constructed by single nucleotide polymorphisms (SNPs) 
provides efficient sequence variation information that can speed up the discovery of genes related to common diseases. In 
this article, we present a generalized linear model for identifying specific nucleotide variants that encode complex human 
diseases. A novel approach is derived to group haplotypes to form composite diplotypes, which largely reduces the model 
degrees of freedom for an association test and hence increases the power when multiple SNP markers are involved. An 
efficient two-stage estimation procedure based on the expectation-maximization (EM) algorithm is derived to estimate 
parameters. Non-genetic environmental or clinical risk factors can also be fitted into the model. Computer simulations 
show that our model has reasonable power and type I error rate with appropriate sample size. It is also suggested through 
simulations that a balanced design with approximately equal number of cases and controls should be preferred to maintain 
small estimation bias and reasonable testing power. To illustrate the utility, we apply the method to a genetic association 
study of large for gestational age (LGA) neonates. The model provides a powerful tool for elucidating the genetic basis of 
complex binary diseases. 
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INTRODUCTION 
  Single nucleotide polymorphisms (SNPs) are the most 
common genomic variations. Detecting the patterns of DNA 
sequence variants across the human genome, particularly the 
patterns of haplotypes, is a crucial step for unravelling the 
genetic basis of complex human diseases. With the growing 
density of SNP data produced by the human HapMap project 
[1,2], association study has been received increasing atten- 
tion in the most recent years. It provides a more efficient and 
powerful way for disease gene discovery than traditional 
linkage methods [3]. 
  The population-based case-control study is a classical 
method for genetic association mapping and has been widely 
applied to disease gene mapping with SNP data collected 
from unrelated individuals. The case-control design has 
substantial practical advantages over a family-based design 
given the fact that it is often difficult to collect DNA samples 
from relatives of affected individuals, especially for late-
onset diseases. In case-control studies, disease-gene associa- 
tion is usually tested by focusing on one single SNP at a time 
using a simple 
2 test by comparing SNP allele frequencies 
between cases and controls [4]. The 
2 test is a detection test 
rather than an estimation test since it does not provide   
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estimates of genetic effects. An alternative approach is to 
apply the logistic regression which can test association and 
estimate genetic effects while adjusting for other covariates 
effects. 
  It is well known that many human diseases are complex, 
which potentially involve multiple disease loci jointly 
functioning to give rise to an affected individual. In general, 
the disease status is a result of additive or multiplicative 
effects of many disease predisposing alleles each having a 
relatively small effect [5]. Methods that test each locus 
separately, hence, is inefficient to detect the disease-gene 
association. Moreover, a significant SNP allele identified by 
a single SNP test may not be the causal mutation for the 
disease, but rather shows a significant association due to 
linkage disequilibrium with a causal mutation [6]. A more 
natural approach would be to understand the genetic basis of 
disease status by analyzing a group of SNPs simultaneously 
through haplotype analysis. The advantage of haplotype 
inference on disease gene mapping over a single-locus 
approach has been shown in several studies [7-9]. Biological 
evidences also confirmed the importance of haplotype 
analysis. For example, studies showed that the alignment of 
multiple functional alleles along a chromosome might have 
great effects on a disease status, where alleles in cis position 
(as a halpotype) within a gene can function jointly to make a 
“super allele” with a large effect on disease phenotypes [10]. 
These statistical and biological evidences underscore the 
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  Precise haplotype inference relies on complete haplotype 
information available for an individual. When linkage phase 
is ambiguous (i.e., more than one heterozygote sites), how- 
ever, direct analysis by assuming known haplotypes is infea- 
sible. A number of statistical approaches have been proposed 
to estimate haplotypes in unrelated individuals (e.g. [11,12]). 
With estimated haplotype frequencies, association can be 
detected by a comparison of haplotype frequencies between 
affected and unaffected individuals [13]. Again, this is a de- 
tection test, and hence, does not provide inference on speci- 
fic haplotype effects. Others considered haplotype effects by 
including possible haplotypes constructed for each individual 
as independent variables in a generalized linear regression 
model setting [10,14-18], and hence ignored the interactions 
of haplotypes inherited from both parents. Moreover, when 
there are many haplotypes fitted in the model, these appro- 
aches could be suffered from potential power loss with large 
number of degree of freedoms. 
 More  recently,  Liu  et al. [19] proposed a statistical 
approach for identifying the distinction of haplotypes and 
estimating haplotype effects on a quantitatively inherited 
trait based on the structural and organizational patterns of 
nucleotide sequences in the human genome [20,21]. This 
approach allows the characterization of DNA sequence 
variants that encode quantitative variation, rather than of 
coarse chromosomal segments as detected by conventional 
linkage mapping. To generalize this approach to dichoto- 
mous disease trait, in this article, we propose a statistical 
mapping approach based on the information provided by 
HapMap project to test disease-gene association adjusting 
for the effects of clinical risk factors. We construct a weigh- 
ted prospective likelihood function with weights modelled as 
a function of relative diplotype frequencies. For an indivi- 
dual with unknown phase, the disease trait density function 
is modelled as a mixture distribution with mixture proportion 
modeled as a function of haplotype frequencies. To reduce 
the model degrees of freedom for an association test, we 
regroup haplotypes to form three composite diplotypes 
regardless the number of SNP loci involved. By hypothe- 
sizing one particular haplotype as the risk haplotype, we can 
do a systematic model selection and hypothesis test to detect 
DNA sequence variants, called binary trait nucleotides 
(BTNs), associated with the phenotypic variation of a binary 
disease trait. BTNs identified by this approach are biologi- 
cally more meaningful than traditional mapping approaches 
aimed to detect quantitative trait loci [22-23]. 
  We develop a two-stage estimation procedure to estimate 
parameters. Model selection criterion such as AIC is used to 
select the risk haplotype. Our model is developed in the 
maximum likelihood context and implemented with the EM 
and Newton-Raphson algorithm. It allows for adjustment of 
nongenetic covariates, such as environmental and clinical 
risk factors, which may provide critical information for 
detecting disease-gene association. Extensive simulation 
studies are performed to investigate the statistical behaviors 
of the model. Specifically, we evaluate the effect of sample 
size, gene action modes and sampling design on the preci- 
sion of parameter estimation, testing power and type I error 
rate. A real example of a study of large for gestational age 
(LGA) neonates is applied to show the application of the 
model, in which significant BTNs are detected in association 
with LGA. 
METHODS 
Definitions and Notations  
  Binary trait nucleotides (BTNs) are defined as DNA 
sequence variants where there exists a distinct haplotype, 
termed as “risk” haplotype, associated with a binary disease 
trait. The biological foundation of the current BTN mapping 
approach is built upon the haplotypes constructed with hap- 
lotype tagging SNPs (htSNPs) located within each haplotype 
block. Due to strong linkage disequilibrium (LD) and low 
haplotype diversity within each block, a small fraction of 
htSNPs could explain a large portion of haplotype diversity 
[20,21,25]. These representative htSNPs greatly facilitate 
genetic association study with reduced cost and improved 
statistical testing power. A number of algorithms has been 
developed for the identification of htSNPs [26-28]. 
  Assume a sample of n unrelated individuals collected 
from a population with n1 affected (cases) and n2 unaffected 
(controls). In this sample, one or more candidate genes are 
selected based on prior knowledge. A number of SNPs are 
then genotyped for each candidate gene. In the current study, 
our interest is to search for the pattern of BTNs that are 
associated with a complex disease. To demonstrate the idea 
of BTN mapping, we first begin with a simple model 
containing only two htSNPs (2-SNP BTN model). A 
generalization for multiple SNPs is given later. 
  Consider two htSNPs within a haplotype block that co-
segregate with the linkage disequilibrium D in the 
population. Each SNP contains two alleles denoted as 1 or 2. 
Let  and  p1
(1) and p2
(1) be the frequencies of alleles 1 and 2 
respectively at SNP 1, and p1
(2) and p2
(2) be the frequencies of 
alleles 1 and 2 respectively at SNP 2. p1
(k) + p2
(k) = 1 for k = 
1,2. Here we use the superscript number for SNP index and 
the subscript for allele index within a SNP. Random 
combination of these two SNPs form 4 possible haplotypes 
denoted as [11], [12], [21] and [22]. Their haplotype 
frequencies are expressed as  
1,2) = (   2 or    1 =     , 1) ( =
2 1
2 1 2 1
) 2 ( ) 1 ( i r D p p p i
r r
r r r r
+  +         (1) 
where 2 1,r r denote the alleles of the two SNPs, respectively, 
and  == =
2
1
2
1 122 1 1
rrr r p . Once haplotype frequencies are 
estimated, allelic frequencies and LD can be obtained by 
solving Equation (1). 
  Random combination of the four maternal and paternal 
haplotypes forms nine observable genotypes (G ) denoted as 
11/11,  , 12/12, , 22/22. The double heterozygotic 
genotype 12/12 contains two possible distinct diplotypes 
[11][22] and [12][21], and hence is phase ambiguous. The 
other eight genotypes are phase-known. Each diplotype 
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distinct phase-known diplotypes expressed as [11][11], 
[11][12], , [22][22] formed by two SNPs. Let  ] ][ [ 2 1 2 1 r r r r P  
and 
2 2 1 1 / r r r r P denote the diplotype and genotype frequencies, 
respectively, and let 
2 2 1 1 / r r r r n  denote the number of 
observations of the above nine genotypes, where  rj = 1 or 2 
( 1,2 = j ). We use upper case P to denote the diplotype 
frequency and lower case p to denote the haplotype 
frequency. Assuming HWE, then ten diplotype frequencies 
can be calculated as a function of the corresponding 
haplotype frequencies, i.e., 
2 1 2 1 2 1 2 1 ] ][ [ r r r r r r r r p p P = . A complete 
list of the genotype and diplotype configurations as well as 
their frequencies is given in Table 1. 
  Without loss of generality, we assume that a disease 
predisposing BTN containing haplotype [11] is associated 
with the disease phenotype. Such a distinct haplotype [11] is 
called the “risk” haplotype. Individuals carrying this specific 
haplotype may potentially have high or low risk to develop a 
disease with a risk level depending on the composition of the 
diplotype structure one carries on. All the other three 
haplotypes are called non-risk haplotypes. To distinguish the 
risk and non-risk haplotypes, we denote all the non-risk 
haplotypes as  ] 11 [ . Random combination of these risk and 
non-risk haplotypes leads to three groupings which are called 
composite diplotypes ( g) expressed as [11][11],  ] 11 [11][  
and  ] 11 [ ] 11 [  (Table 1).  
  The regrouping method is biologically intuitive and sta-
tistically efficient. By formulating the composite diplotype, 
the additive and dominant effects of a risk haplotype can be 
estimated. Also, we could greatly reduce the number of pa-
rameters in the regression model. For example, when there 
are  m  SNPs considered, there could be 2m  haplotype pa-
rameters need to be estimated for a full haplotype regression 
model and 2
m-1(2
m+1) parameters need to be estimated for a 
full diplotype model. When m is large, this could cause over-
fitting problems. Moreover, large number of degree of free-
dom could decrease the power for an association test. With 
our formulation, there are always three composite diplotypes 
regardless of large number of SNPs.  
Multiple Logistic Regression Model 
 Let  y denote a measured disease trait which takes two 
values, 1 or 0, corresponding to affected or control respec-
tively. Let Xg  denote a matrix of numerical codes corre-
sponding to the composite diplotype, g, including the inter-
cept as the first column, and let Xe denote a matrix of meas-
ured clinical risk factors. Assuming that all these covariates 
influence the mean of the trait and not the scale, so that their 
effects can be summarized by a function of linear predictors 
   = Xg + Xe = X               (2) 
where  contain regression parameters for the intercept and 
the genetic effects of composite diplotypes on a disease trait; 
 contain the effects of clinical risk factors;  ) , ( = e g X X X  
Table  1.  Possible Diplotype and Composite Diplotype Configurations of Nine Genotypes at Two SNPs and their Haplotype 
Composition Frequencies 
Diplotype Composite  Diplotype 
Genotype 
Configuration Frequency Relative  Frequency  Symbol  Diplotype  Function 
No. of Observation 
11/11 [11][11] 
2
11 [11][11] = p P   1 [11][11]  2   
11/11 n  
11/12 [11][12]  12 11 [11][12] 2 = p p P   1  [11][ 1 1 ]  1    11/12 n  
11/22 [12][12] 
2
12 [12][12] = p P   1  [ 1 1 ][ 1 1 ]  0   
11/22 n  
12/11 [11][21]  21 11 [11][21] 2 = p p P   1  [11][ 1 1 ]  1    12/11 n  
12/12 



[12][21]
[11][22] 



21 12 [12][21]
22 11 [11][22]
2 =
2 =
p p P
p p P  





1
 
 



] 11 ][ 11 [
] 11 [ ] 11 [  



 1
1
1 
  
12/12 n  
12/22 [12][22]  22 12 [12][22] 2 = p p P   1  [ 1 1 ][ 1 1 ]  0   
12/22 n  
22/11 [21][21] 
2
21 [21][21] = p P   1  [ 1 1 ][ 1 1 ]  0   
22/11 n  
22/12 [21][22]  22 21 [21][22] 2 = p p P   1  [ 1 1 ][ 1 1 ]  0   
22/12 n  
22/22 [22][22] 
2
22 [22][22] = p P   1  [ 1 1 ][ 1 1 ]  0   
22/22 n  
 =
p11p22
p11p22 + p12p21
 where p11 ,  p12 ,  p21 and p22 are the frequencies for haplotype [11], 12, 21, and 22, respectively. The relative frequency refers to the probability that a 
specific diplotype is observed. For unambiguous genotype (phase known), the relative frequency is 1. For the double heterozygotic genotype 12/12, the probability of observing 
diplotype [11][22] is , and observing diplotype [12][12] is 1- . 310    Current Genomics, 2007, Vol. 8, No. 5  Cui et al. 
and   = (,  ). Given a binary disease response, we can 
apply the logit model which corresponds to the natural logit 
link function with the form  



 = )
1
( = ) ( logit

log  
with the logistic distribution function 
) ( 1
) (
= ) ( =


 
exp
exp
h
+
 
  A logistic regression model has been broadly applied to 
the modelling of binary data [29,30]. Given covariates value 
x, the probability distribution of a disease status  Y = y for an 
individual i can be expressed as  
 
(yi | xgi,xei)=
exp{(   j xgi  j
j'=0
2
 +  jxeij
j=1
p
 )yi}
1+ exp(   j xgi  j
j'=0
2
 +  jxeij
j=1
p
 )
,  i =1,,n
                       ( 3 )  
where  yi takes value 1 or 0, xgi0 is one for all i, the 
independent variables xgi1  and xgi2 are defined as  





 ] 1 1 ][ 1 1 [   diplotype   composite for       1
] 1 1 [11][   diplotype   composite for         0
[11][11]   diplotype   composite for         1
= 1 gi x          (4) 
 and  



otherwise        0
] 1 1 [11][   diplotype   composite for         1
= 2 gi x          (5) 
and variables  eij x ( ) , 1, = p j   refers to the p clinical non-
genetic covariates of interest. 
  With the coding mechanism defined in (4) and (5), 1 
and  2 can be considered as the additive and dominant 
genetic effect of a risk haplotype [31], 0  is the intercept 
and 
j   ( ) , 1, = p j   is the non-genetic covariate effect. If 
either parameter estimate, 1 or 2, is positive, the risk 
haplotype [11] triggers a positive effect to increase a disease 
risk. The effect of BTNs is considered as pure additive, 
dominant or recessive if the ratio of the dominant over 
additive effect (2 /   1) is 0, 1 or -1 respectively, and is 
considered as semi-dominant or over-dominant if the 
absolute value of this ratio is less than 1, or greater than 1 
respectively. We call parameters contained in  = (,  ) 
quantitative parameters to distinguish them with the 
population parameters defined in Eq. (1). 
  We can further partition the logistic function defined in 
(3) into three distinct logistic regression functions corres- 
ponding to different composite diplotype groups as follows  
) exp( 1
} ) {(
= ) , | ( =
1 1 0
1 1 0
2 2  + + +
 + +
=
=
p
j eij j
i
p
j eij j
ei gi i x
y x exp
x x y
  
  
 
                        (6) 
for composite diplotype [11][11], and  
) exp( 1
} ) {(
= ) , | ( =
1 2 0
1 2 0
1 1  + + +
 + +
=
=
p
j eij j
i
p
j eij j
ei gi i x
y x exp
x x y
  
  
 
                       ( 7 )  
for composite diplotype [11][ 1 1 ], and  
) exp( 1
} ) {(
= ) , | ( =
1 1 0
1 1 0
0 0  +  +
 + 
=
=
p
j eij j
i
p
j eij j
ei gi i x
y x exp
x x y
  
  
 
                       ( 8 )  
for composite diplotype [ 1 1 ][ 1 1 ]. 
  We define these three distinct logistic functions as the 
diplotype functions corresponding to different diplotypes 
illustrated in Table 1. 
Likelihood Function and Parameter Estimation 
  The logistic regression model links the interpatient 
variation in a disease trait (y) with the observed SNP 
genotypes (G ). Our goal is to detect DNA sequence variants 
or BTNs underlying a disease trait. As shown in Table 1, 
most genotypes have one to one relationship with their 
diplotypes except the one with genotype denoted as 12/12. 
This double heterozygote can be partitioned into two 
possible diplotypes, [11][22] and [12][12] with relative 
frequencies  and 1 – , respectively. Let p(gi | Gi ) denote 
the relative frequency for a diplotype gi consistent with the 
observed genotype Gi. The relative frequencies for all 10 
possible diplotypes are given in Table 1. For individuals with 
known phase, ( p(gi | Gi ) takes value one. The individual 
contribution to the likelihood is given by  
Li()  
D g
i i
i
x y ) | ( =   p(gi | Gi ) 
where D denotes all possible diplotypes that are consistent 
with the observed marker genotype. For an individual with 
known phase, Li() =  (yi | xi). For an individual with 
genotype 12/12, its likelihood contribution follows a mixture 
distribution with the form  
 
Li()  ) | ( =
D g
i i x y
i
 

 p(gi | Gi )  ) | ( ) (1 ) | ( = 0 1 i i i i x y x y     +
                       ( 9 )  
where the mixture proportion  
12 12 22 11
22 11 =
p p p p
p p
+
  
represents the relative frequency of subject i whose 
diplotype is [11][22], and  ) | ( 1 i i x y   and  ) | ( 0 i i x y   are the 
logistic regression functions defined in model (7) and (8), 
respectively. 
  Assuming independence among individuals, the joint 
prospective likelihood function can be expressed as  
  L()  =
1 =
n
i
L  Li()             (10) Nucleotide Mapping of Binary Disease Traits  Current Genomics, 2007, Vol. 8, No. 5    311 
  Noted that the likelihood formulation in (10) is different 
from the one proposed by Lake et al. [15] in which the 
likelihood function is given as a weighted sum with weights 
modeled as a function of haplotype frequencies rather than 
relative diplotype frequencies. 
  For a 2-SNP model, the log-likelihood function of the 
observed data can be further partitioned as  
n  ()
  log = L
 L() = 
)] | ( ) (1 ) | ( [ log    
) | ( log
) | ( log ) | ( log   
0 1
1 =
0
1 =
1
1 =
2
1 =
12 / 12
22 / 22 12 / 22 11 / 22 22 / 12 22 / 11
11 / 12 12 / 11 11 / 11
i i i i
n
i
i i
n n n n n
i
i i
n n
i
i i
n
i
x y x y
x y
x y x y
  

 
 + +
+
+


 
+ + + +
+
 
                   ( 1 1 )  
  The maximum likelihood estimate 
j  ˆ ( 2 , 0, = + p j  ) 
contained in  can be obtained by solving the score equation: 
n  () 0 = )/ j   . A computational algorithm based on the 
Expectation-Maximization (EM) algorithm [32] can be 
formulated to find  j  ˆ, with the Newton-Raphson algorithm 
embedded in the M-step (See Appendix for detailed 
derivations). Standard model diagnostic approaches such as 
goodness-of-fit test can be applied to check the model fitting 
[33]. We array this set of quantitative parameters which 
include genetic and nongenetic parameters based on Model 
(3) as q = () = (, ). 
  The above algorithm is implemented assuming that  is 
known. In reality, we do not know  and it needs to be 
estimated from the data. To estimate , we need to estimate 
the four haplotype frequencies which is arrayed as 
) , , , ( = 22 21 12 11 p p p p p  . Once we estimate 
p  ,   can be 
estimated by plugging in the MLE of 
p  . 
  The four haplotype frequencies can be estimated based 
on the nine observed genotypes () for two SNPs (Table 1). 
Assuming HWE, the log-likelihood function of the unknown 
haplotype frequencies given observed genotypes can be 
written as a multinomial distribution  
 
log L(p | G )  
22 22/22
22 21 21/22 21 21/21 22 12 12/22
21 12 22 11 12/12 21 11 12/11
12 12/12 12 11 11/12 11 11/11
log 2   
) (2 log log 2 ) (2 log   
)] [2( log ) (2 log   
log 2 ) (2 log log 2
p n
p p n p n p p n
p p p p n p p n
p n p p n p n
+
+ + +
+ + +
+ +
 
  Again, we have a missing data problem since the two 
distinct diplotypes for genotype 12/12 can not be observed 
explicitly. This problem can be solved by applying the EM 
algorithm (See [19] for a detailed EM procedure). With the 
estimated haplotype frequencies, we can also solve Equation 
(1) to obtain the estimates of the SNP allele frequencies and 
the LD parameter. 
 The  estimated   , denoted as  ˆ, is then plugged into the 
likelihood function (11) to obtain the parameter estimation 
contained in 
q  . Since we estimate parameters contained in 
q   and 
p   separately, this estimation procedure is also 
called a two-stage estimation procedure. Noted that the 
parameters contained in 
q   do not heavily rely on the 
estimated haplotype frequencies, especially when the double 
heterozygous rate is low. Thus, the estimation procedure is 
quite robust to departure from HWE. Both EM algorithms 
for estimating  q and p converge very fast. 
Hypothesis Tests 
  To detect the association between a disease and BTNs 
and fully dissect the genetic effects of BTNs, a series of 
hypotheses can be conducted. The existence of significant 
BTNs on a complex disease trait can be tested based on the 
following hypotheses  



0   equal not    does   parameters    the of   one least  at  :
0 = = :
1
2 1 0
H
H       (12) 
  A general approach is to use the likelihood ratio test, 
where the test statistic is calculated by comparing the 
likelihood values under the alternative hypothesis  1 H  to the 
null hypothesis  0 H  for the significance of BTNs using  
| 0 = = , ~ , ~ ( log 2[ = L 2 1 0 1 L R       G ) – log L( ˆ,  ˆ | G )] 
where the parameters with tilde and hat denote the MLEs of 
unknown parameters under  0 H  and  1 H , respectively. 
Assuming fixed  in the likelihood function (11), the 
regularity conditions for asymptotic 
2   distribution of LR 1 
hold as long as the number of observations  12/11 11/12 n n +  and 
22/22 22/12 22/11 12/22 11/22 n n n n n + + + +  are of comparable size 
with  12/12 n . So the LR1 asymptotically follows a 
2   
distribution with two degrees of freedom [34]. 
  Upon rejection of  0 H  in the above test, we can further 
test whether the BTNs exert a significant additive haplotype 
effect or dominant haplotype effect on a disease trait by 
simply formulating  
  




=
0 :
0 :
1 1
1 0


H
H               (13) 
for testing additive effect and  
  




=
0 :
0 :
2 1
2 0


H
H              (14) 
for testing dominant effect. 312    Current Genomics, 2007, Vol. 8, No. 5  Cui et al. 
  Again, the likelihood ratio test can be applied which is 
asymptotically 
2  -distributed with one degree of freedom. 
  We can also test the allelic association between two 
SNPs by testing the LD between them with hypotheses:  
  



 0 :
0 = :
1
0
D H
D H               (15) 
  The log-likelihood ratio test statistic (LR2) can be 
similarly calculated as  
| 0 = , ~ , ~ ( log 2[ = L
) 2 (
1
) 1 (
1 2 D p p L R   G ) – log  | ˆ ( p L   G )] 
 The  LR2 is considered to asymptotically follow a 
2   
distribution with one degree of freedom. The MLEs of allelic 
frequencies under  H0 can be estimated using the EM 
algorithm described above, but with the constraint 
21 12 22 11 = p p p p . 
  The effect of non-genetic covariates on a disease trait can 
also be tested in a similar way using likelihood ratio test. 
Since the association test (12) is conducted after adjusting 
for the effects of clinical risk factors, it is more informative 
than the retrospective likelihood approaches (e.g. [14,16]) 
which do not adjust for the effects of clinical risk factors. 
Risk Haplotype Selection and Statistical Inferences 
  The above model is developed by assuming that 
haplotype [11] is the risk haplotype. In reality, we have no 
prior information on which genetic component triggers a 
potential effect on a disease trait. We adopt the theoretical 
information criterion approach to select the risk haplotype. 
Among a pool of criteria, the Akaike's information criteria 
(AIC) has been widely used in a variety of fields for model 
selection [35]. For a 2-SNP model, there are 4 possible 
haplotype structures. By assuming each one of the haplo- 
types as the risk haplotype, we can calculate the AIC infor- 
mation one at a time for each hypothesized risk haplotype as  
  AIC = –2 ln L( | s) + 2ps           (16) 
where  s refers to the sth haplotype and ps refers to the 
number of parameters by taking the sth haplotype as the risk 
haplotype. The one which achieves the minimum AIC value 
is then subject to statistical test based on test (12). 
Significant BTNs are detected to be associated with a disease 
if a significant risk haplotype exists. When there are multiple 
haplotype blocks involved, corrections for multiple testing 
using false discovery rate (FDR) approach is required [36]. 
  A number of statistical inferences can be formulated 
based on the current BTN model. If significant BTNs are 
detected, one might be interested in quantifying the disease 
odds or odds ratio. The disease odds can be calculated for 
individuals carrying different haplotype structures and are 
exposed to different clinical conditions. For example, the 
odds of a disease for an individual carrying composite 
diplotype [11][11] can be calculated as  
) ( =
) , | 0 = (
) , | 1 = (
=
1 =
1 0 [11][11] eij j
p
j ei gi i
ei gi i x exp
X X y p
X X y p
odds     + +  
  Thus the exponential of the parameters gives rise to a 
factorial contribution to the odds not only subject to clinical 
exposure but also to diplotype structure. Even though 
individuals are exposed to the same clinical condition, the 
chance to be affected varies depending on the diplotype 
structures they carry on. For example, the odds ratio of a 
disease for an individual carrying composite diplotype 
[11][11] and [11][11] after controlling for other covariates 
can be computed as  
= ( )/ 1, = | 1 = (
= ( )/ 1, = | 1 = (
=
2
2
] 1 1 ][ 1 1 [11][11]/[ y p X X y p
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                             ) (2 =
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1
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X X
X X
ei i g
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
 
  Using delta method, the confidence interval of the odds 
ratio can be obtained [33]. Note that the intercept 0 does not 
represent population prevalence for a case-control sample. 
Multilocus BTN Model 
  The idea of BTN mapping based on a two-SNP model 
can be extended to include an arbitrary number of SNPs 
whose sequence variants are associated with the disease 
variation. ConsiderK 3) (  K  htSNPs within a haplotype 
block constructed from a number of bi-allelic loci. Each of 
these  K  htSNPs contains two alleles denoted by 
) 1, = 1,2; = ( K k r Q k
k
rk  , with allele frequencies denoted by 
) (k
rk p  for the k th htSNP. The coding form indicates that 
alleles with the same value of  k r  are located on the same 
chromosome. 
  One of the key issues for the multi-SNPs model is to 
clearly formulate the haplotype and diplotype structures 
across the K  multilocus htSNPs. There are totally 
K 2  
possible haplotypes can be formed by the random 
combination of these K htSNPs. A general form of these 
haplotypes is expressed as  K Q Q Q
k r r r  2 1
2 1
 with corresponding 
haplotype frequencies denoted by 
K r r r p ... 2 1 . These K htSNPs 
form
K 3 observable multilocus zygotic genotypes expressed 
as  
K Q K Q Q Q Q Q
K s K r s r s r / / 2 2 / 1 1
2 2 1 1   
with corresponding genotype frequency and observation 
expressed as 
K Ks r s r s r P / / / 2 2 1 1 
 
and  
K Ks r s r s r n / / / 2 2 1 1 
 
respectively. The random combination of haplotypes derived 
from maternal and paternal parents generates  1) (2 2
1 +
 K K  
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] 2 1 ][ 2 1 [
2 1 2 1
K Q Q Q K Q Q Q
K s s s K r r r    
with corresponding diplotype frequency expressed as  
K K K K s s s p r r r p s s s r r r P     2 1 2 1 2 1 2 1
= ] ][ [
 
assuming HWE. The composite diplotype can be formulated 
in a similar way as illustrated in the 2-SNP model. 
  As illustrated in the 2-SNP BTN model, the number of 
multilocus diplotype is generally greater than the number of 
genotypes when there are two or more heterozygotes present. 
For example, for a 3-SNP model, the genotype 
3
2
3
1
2
2
2
1
1
1
1
1 / / Q Q Q Q Q Q  could form two different diplotypes 
expressed as  ] ][ [
3
2
2
2
1
1
3
1
2
1
1
1 Q Q Q Q Q Q  and  ] ][ [
3
1
2
2
1
1
3
2
2
1
1
1 Q Q Q Q Q Q , 
while the genotype 
3
2
3
1
2
2
2
1
1
2
1
1 / / Q Q Q Q Q Q  could form four 
different diplotypes. If we assume that 
3
1
2
1
1
1 Q Q Q  is the risk 
haplotype, the three composite diplotypes can be formulated 
as [
3
1
2
1
1
1 Q Q Q ][
3
1
2
1
1
1 Q Q Q ], [
3
1
2
1
1
1 Q Q Q ][
3
1
2
1
1
1 Q Q Q ] and [
3
1
2
1
1
1 Q Q Q ] 
[
3
1
2
1
1
1 Q Q Q ]. 
  The multilocus haplotype frequency can be formulated as 
a function of allele frequencies and LD parameters of 
different orders [37]. For example, a haplotype frequency, 
denoted as 
L r r r p  2 1
, can be decomposed into the following 
components:  
where  D's are the linkage disequilibria of different orders 
among particular htSNPs. 
  The MLEs of quantitative parameters can be estimated 
by formulating the likelihood function similar to the 2-SNP 
model. The EM algorithm can be employed to estimate the 
MLEs of haplotype frequencies, and the quantitative 
parameters. The AIC-based model selection procedure can 
be adopted to select the risk hapltoype. 
RESULTS 
Simulation Study 
  We perform a series of Monte Carlo simulations to 
investigate the statistical behavior of the proposed BTN 
mapping approach. The simulation is designed to evaluate 
the model performance considering the effects of sample 
sizes ( 100,200 = n  and 500), gene action mode (additive, 
dominant, and recessive), and sampling design on the 
precision of parameter estimations, type I error rates as well 
as the power to detect the association. 
  Assuming that one haplotype is distinct from the other 
ones, haplotype frequencies are calculated based on the 
given allele frequencies and LD parameter as listed in Table 
3. Then distinct diplotypes are simulated according to a 
multinomial distribution with a probability for each 
diplotype calculated from their corresponding haplotype 
frequencies assuming HWE. A disease status is simulated 
from a bernoulli distribution with a probability of success 
defined in model (3) with  1 = i y . For simplicity, we only 
consider one covariate in the model and it is simulated from 
a standard normal distribution. The given values for 
population and quantitative parameters are listed in Table 3. 
The data simulated with this distinct BTN structure are 
subject to statistical analysis. 
  In each simulation scenario, 1000 Monte Carlo repeti- 
tions are performed. For each Monte Carlo sample, the EM 
algorithm is used to obtain the MLE's of the haplotype 
frequencies, allele frequencies and LD parameter as well as 
the quantitative parameters which include the genetic and 
non-genetic covariates effects. The MLEs for all parameters 
are listed in Table 3 and their square root of the mean 
squared errors (RMSEs) are given in the parenthesis. The 
proportion of cases for the simulated data is about 40-50% 
on average under the three gene action modes. 
  As expected, the true association can only be detected 
with the hypothesized risk haplotype, and all the parameters 
can be accurately estimated only under the correct haplotype 
distinction. Overall, our model provides reasonable para- 
meter estimation under different simulation scenarios. All 
population parameters including the allele frequencies and 
LD parameter can be well estimated with high precision. The 
precision depends only on sample size and is not affected by 
gene action modes. Large sample size always leads to low 
bias and high precision (Table 3), which infers the consis- 
tency of the parameter estimation. 
  With the estimated haplotype frequencies, we carry out 
the second stage estimation to estimate the quantitative 
parameters. As can be seen from Table 3, the estimation 
precision of quantitative parameters depends not only on 
sample size, but also on gene action modes. In general, 
trends hold across different simulations are evident. First, the 
accuracy and precision of all parameter estimation increase 
as the sample size increases. Small sample size ( 100 = n ) 
results in poor parameter estimation and the precision is 
dramatically improved when sample size is increased from 
100 to 200. Second, as expected, the additive effect can be 
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better estimated than the dominant effect in all simulations. 
For instance, the RMSE for additive effect is 30% smaller 
than the dominant effect under the dominant model with 
sample size 200. Third, the nongenetic covariate effect is not 
sensitive to the gene action mode, whereas the genetic 
parameters act differently under different gene action modes. 
  Type I error evaluation is summarized in Table 2 at the 
0.05 nominal level with sample sizes ranging from 100 to 
500. It can be seen that the estimated type I error rates are 
not appreciably different from the nominal level 0.05. For 
power analysis, we consider three disease models: additive, 
dominant, and recessive as given in Table 3. The testing 
power is defined as the percentage of simulations in which 
the true association is detected. For each simulation case, we 
run 1000 replicates. The results show that the power of an 
association test statistic depends on a number of parameters, 
such as the sample size and the gene action modes. As 
expected, the testing power increases as the sample size 
increases. For example, assuming additive model, the power  
 
Table 2.  The Type I Error Estimated from 1000 Simulation 
Replicates Under the 2 and 3-SNP Models with 
Nominal Level 0.05 
n  2-SNP model  3-SNP Model 
100 0.073 0.06 
200 0.056  0.055 
300 0.058  0.054 
400 0.045  0.049 
500 0.047  0.048 
 
Table 3.  The Mean MLEs with their Square Root Mean Square Errors (RMSEs) (in Parentheses) of Population and Quantitative 
Parameters of the BTNs Estimated from 1000 Simulation Replicates Under the 2-SNP Model 
n   0 = 0.5   1 = 1   2   = 1.5  p
1
(1) = 0.7  p
1
(2) = 0.7  D = 0.02  Power 
Additive      2  =   0        
100  0.582 1.082 -0.067 1.618 0.698 0.701 0.021  64 
  (0.695) (0.686) (0.818) (0.403) (0.033) (0.032) (0.021)   
200  0.505 1.051 0.015 1.565 0.701 0.699  0.02  93.3 
  (0.278) (0.314) (0.407) (0.269) (0.024) (0.024) (0.016)   
500 0.510  1.007  -0.006  1.521 0.7  0.7  0.02  100 
  (0.176) (0.188) (0.252) (0.160) (0.015) (0.014) (0.009)   
Dominant      2  =   1        
100  0.586 1.089 1.008 1.643 0.698 0.701 0.021  74.8 
  (0.718) (0.710) (0.887) (0.468) (0.033) (0.033) (0.021)   
200  0.523 1.038 1.013 1.557 0.701  0.7  0.02  96.4 
  (0.279) (0.308) (0.423) (0.284) (0.023) (0.023) (0.015)   
500  0.506 1.009 1.002 1.518  0.7  0.7  0.02  100 
  (0.169) (0.191) (0.265) (0.166) (0.015) (0.014) (0.009)   
Recessive      2  =     - 1        
100  0.581 1.098 -1.119 1.622 0.699 0.699 0.019  88 
  (0.789) (0.798) (0.919) (0.418) (0.032) (0.034)  0.022   
200 0.519  1.040  -1.036  1.572 0.7 0.699  0.02 97.6 
  (0.287) (0.316) (0.421) (0.269) (0.023) (0.023)  0.015   
500 0.504  1.016  -1.013  1.530 0.7 0.699  0.02 100 
  (0.186) (0.182) (0.261) (0.164) (0.015) (0.015) (0.009)   
p1
(1) ,  p1
(2)  and  D  are the allelic frequencies of alleles Q1
1  and Q1
2  at two SNPs and their linkage disequilibrium, respectively. 0  is the intercept, and 1  and 2  are the 
additive and dominant effects respectively by assuming that haplotype [Q1
1Q1
2 ] is different from the rest haplotypes.   is the covariate effect. The first row contains the given 
values of all parameters. Power is calculated as the percentages of all simulations in which the true disease-gene association is detected. Nucleotide Mapping of Binary Disease Traits  Current Genomics, 2007, Vol. 8, No. 5    315 
increases from 64% to 93.3% when the sample size increases 
from 100 to 200. Simulation results also show that the test 
power is sensitive to gene action mode for small sample size 
( 100 = n ). When sample size increases to 200, we observe 
dramatic power improvement and the difference among 
different gene action modes is no longer remarkable. 
  Our association test is conducted based on a prospective 
likelihood setting assuming a random sample from a popu- 
lation. To evaluate the effect of sampling design on para- 
meter estimation and testing power, we simulate samples 
through changing the intercept 0 by holding other parame- 
ters unchanged as given in Table 3. The value of intercept 
determines the proportion of cases in a sample. Fig. (3) plots 
the effects of case proportions on the type I error rate with 
sample size 100 and 200. It can be seen that the type I error 
rates are inflated when the proportion of cases is away from 
50%. As long as the case proportion is kept within the 30%-
70% range, the false positive rate can be appropriately con- 
trolled. Figs. (1) and (2) plot the effect of case proportions 
on the testing power and the absolute averaged bias of 
parameter estimation under three disease models out of 1000 
simulations. Clearly, the testing power and estimation biases 
are affected by case proportions. The power is greatly 
reduced and the parameter estimation is severely biased 
when the case proportion is far away from 50% for small 
sample size (say 100). As sample size increases to 200, the 
power is significantly increased and the bias is dramatically 
reduced. Higher sample size (500) leads to more dramatic 
improvement (data not shown). However, to achieve desired 
power and small bias, we still need to maintain a balanced 
case-control sample. When sample size is small (say less 
than 100), maintaining such a balance is even more crucial. 
  To test the performance of multi-SNP model, a simula-
tion study assuming 3 htSNPs in a haplotype block is 
performed. The simulation design is similar to the 2-SNP 
model. The results are summarized in Table 4. In general, we 
observe similar trends for both population and quantitative 
parameters as in the 2-SNP model. As compared to the 2-
SNP model, a slightly higher testing power is observed 
compared to the 2-SNP model with 100 sample size, espe- 
cially under the dominant gene action mode. When sample 
size increases to 200 or 500, the difference is not remarkable. 
Similar results are observed for case proportion effect as in 
the 2-SNP model and hence is omitted. 
A Case Study 
  We apply our model to a genetic association study of 
LGA neonates. LGA may lead to complications for both 
newborns and mothers. Studies showed that LGA is 
associated with increased risk of infant mortality [38], and 
may further lead to development of overweight for a baby in 
later stage of life [39, 40]. Risk of mothers of LGA neonates 
includes prolonged labor [41], risk of postpartum bleeding 
and genital tract injury [42]. Increasing proportion of LGA 
infants born has been reported in recent years [43, 44], but 
the etiology of LGA remains largely unknown. It has been 
increasingly recognized that complication of pregnancy and 
delivery is a complex trait determined by multiple environ- 
mental and genetic factors [45], few genetic association 
studies have been reported in literature on the relationship 
between genetic factors and LGA. 
 
A 
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Fig. (1). The effect of case proportion on testing power under 
different sample sizes under the additive model (A), dominant 
model (B), and recessive model (C). Testing power is defined as the 
proportion of simulations (1000 Monte Carlo simulations) in which 
significant associations are detected. 
  To understand the genetic basis of LGA, a number of 
candidate genes have been genotyped for SNPs. Here we 
only use one of them to demonstrate the model implemen- 316    Current Genomics, 2007, Vol. 8, No. 5  Cui et al. 
tation. Our goal is to study which genetic factors in mother 
are associated with the LGA neonates. The data set contains  
552 unrelated maternal individuals with 117 cases and 435 
controls in ages ranging from 13 to 45 years old mothers 
recruited at the Sotero del Rio Hospital, in Puente Alto, 
Chile. Each of these subjects was genotyped for SNP 
markers within the candidate gene apolipoprotein C-III 
(APOC3) located at chromosome 11q23. There are total 6 
positions showing polymorphisms, three at the intron 1 
region for SNPs 633938761, 633938806, and 633938845, 
one at exon 3 region for SNP 633938988, one at intron 3 
region for SNP 633939053 and one at exon 4 region for SNP 
633939147. We use Haploview software to construct the 
haploype block [46]. The haplotype block is defined using 
the confidence intervals definition [21]. Fig. (4) shows that 
there are two haplotype blocks with block I containing two 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The effect of case proportion on parameter estimations under different sample sizes and different disease models. The vertical line 
represents the averaged absolute bias for each parameter from 1000 Monte Carlo simulations. Nucleotide Mapping of Binary Disease Traits  Current Genomics, 2007, Vol. 8, No. 5    317 
SNPs 633938806 and 633938845 and block II containing 
three SNPs 633938988, 633939053 and 633939147. SNP 
633938761 does not belong to any blocks. No SNPs are 
significant using the single SNP x
2 test implemented in 
Haploview. Also, no haplotypes are significant in block II 
and one haplotype (TC) is significant in block I using the 
haplotype test implemented in Haploview. 
  We apply our newly developed method to analyze this 
data set. We fit the 2-SNP model for SNPs in block I and the 
3-SNP model for SNPs in block II. Results show that only 
SNPs in block I are significantly associated with LGA. In the 
following, we only focus our analysis on SNPs in block I. 
The two SNPs in block I form four haplotypes designated as 
TG, TC, CG, and CC. The two SNPs are in linkage disequi- 
librium, which suggests the importance of considering haplo- 
type effect on the association study, rather than based on a 
single SNP. Five clinical risk factors are included in the 
model, maternal age (MA), maternal weight (MW), number 
 
 
 
 
 
 
 
 
 
 
Fig. (3). The effect of case proportion on type I error under 
different sample sizes. Type I error is defined as the proportion of 
simulations (1000 Monte Carlo simulations) in which false 
associations are detected with data simulated under the null of no 
association, i.e., 1 = 2 = 0. 
Table 4.  The Mean MLEs with their Square Root Mean Square Errors (RMSEs) (in Parentheses) of Population and Genetic 
Parameters of the BTNs Estimated from 1000 Simulation Replicates Under the 3-SNP Model 
n   0   1   2   p
1
(1)   p
1
(2)  p
1
(3)  D12  D13  D23  D123 Power 
True*   0.5   1.0      1.5   0.7   0.7   0.7   0.04   0.025   0.025   0.02   
Additive      2  =     0            
100   0.622   1.156   -0.117   1.614   0.698   0.699   0.699    0.04    0.025   0.024    0.02   68.8 
  (0.998)      0.992)   (1.076) (0.405) (0.033) (0.033) (0.033) (0.020) (0.021) (0.021) (0.013)   
200   0.542    1.038   -0.028    1.547    0.699   0.700   0.699   0.04   0.026   0.024   0.02   93.1 
  (0.307)    (0.311) (0.413) (0.245) (0.023) (0.023) (0.024) (0.014) (0.015) (0.015) (0.009)   
500   0.504    1.013    -0.004    1.522    0.700    0.700    0.699    0.04    0.025    0.024    0.02    100 
    0.179)     0.186) (0.256) (0.159) (0.015) (0.015) (0.016) (0.009) (0.009) (0.009) (0.006)   
Dominant     2  =     1            
100   0.677   1.201    0.975    1.654    0.700    0.699    0.699    0.04    0.025    0.024    0.02    83.2  
  (1.276) (1.302) (1.566) (0.480) (0.033) (0.033) (0.033) (0.020) (0.021) (0.020) (0.013)   
200   0.544   1.036    0.997    1.547    0.699    0.700    0.699    0.04    0.026    0.024    0.02    99.2 
  (0.305) (0.318) (0.459) (0.274) (0.023) (0.023) (0.024) (0.014) (0.015) (0.015) (0.009)     
500   0.506    1.012    1.013    1.521    0.700    0.700    0.699    0.04    0.025    0.024    0.02    100 
  (0.178) (0.190) (0.281) (0.169) (0.015) (0.015) (0.015) (0.009) (0.009) (0.009) (0.006)   
Recessive      2  =     - 1            
100   0.637   1.18   -1.151   1.631   0.702   0.701   0.702   0.04   0.025   0.024   0.02  89.3 
  (1.128)  (1.15)  (1.217) (0.429) (0.033) (0.033) 0.032)  0.021)  0.021)  0.021) (0.013)   
200  0.52  1.032 -1.025 1.552 0.699  0.7  0.7  0.04  0.026 0.024  0.02  97.8 
  (0.299) (0.296) (0.438) (0.262) 0.024) (0.023) 0.023)  0.014) (0.015) (0.015) (0.009)   
500  0.502  1.01  -1.01 1.521 0.700 0.700 0.699  0.04  0.025 0.024  0.02  100 
  (0.183) (0.193) (0.262) (0.153) (0.015) (0.015) (0.015) (0.009) (0.009) (0.009) (0.006)   
p1
(1) ,  p1
(2)  and  p1
(3)  are the allelic frequencies of alleles Q1
1 ,  Q1
2  and Q1
3  at three SNPs, and  D12 ,  D23 ,  D13 , and  D123  are their linkage disequilibrium, respectively by 
assuming that haplotype [Q1
1Q1
2Q1
3]  is different from the rest haplotypes. See Table 3 for explanations of other parameters. 318    Current Genomics, 2007, Vol. 8, No. 5  Cui et al. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). The haplotype block view constructed with Haploview 
[46]. The values shown on the plot are the Lewontin's D'. The 
blocks are defined based on the confidence intervals definition [21]. 
The six SNPs form two haplotype blocks with one containing two 
SNPs and the other one containing three SNPs. SNPs 633938761 
does not belong to either of the two blocks. 
of preterm deliveries (PTD), baby sex (BS), and maternal 
body mass index (MBMI). Our aim is to detect haplotype 
variants within this candidate gene which are associated with 
LGA under a variety of environmental conditions. 
  By assuming that one haplotype is different from the rest 
of the haplotypes, we performed a systematic test for the 
four haplotypes. The results are summarized in Table 5. The 
MLEs of the haplotype frequencies, allele frequencies and 
the LD parameter are given. These two SNPs are strongly 
associated with each other ( 0.1577 = ˆ  D ). The estimated 
allele frequencies are 0.7455 for allele T in SNP 633938806 
and 0.3806 for allele C in SNP 633938845. The heterozygote 
rate for the two SNPs are 40% and 48%, respectively. The 
smallest AIC value is observed for haplotype TC which also 
shows significance based on hypotheses test (12) (p-
value=0.024). All the other three haplotypes do not show 
evidence of significance. 
  The MLEs of the quantitative parameters and their 
standard errors in the parenthesis are listed in Table 5. The 
likelihood ratio test shows that both additive and dominant 
effect for haplotype TC are significant at the 0.01 level. 
Table  5.  The Maximum Likelihood Estimates (MLEs) of the Population and Quantitative Parameters for Significant BTNs 
Associated with LGA Detected within APOC3 Gene. The Standard Errors of the Quantitative Parameters are Given in 
the Parenthesis 
   AIC  LR1  P - value 
[TC]  558.2  7.429  0.024 
[TG]   565.29  0.336 0.845 
[CG]  - - - 
Risk haplotype 
[CC]  562.68  2.948 0.229 
Population parameters      
G pT ˆ  0.6196     
TC p ˆ  0.1259     
G pC ˆ  0     
Haplotype frequencies 
C pC ˆ  0.2545     
1 ˆT p  0.7455     
2 ˆC p  0.3804      Allele frequencies and LD 
D ˆ  -0.1577     
Quantitative parameters      
Intercept 
0 ˆ   -3.235(0.851)     
Additive effect 
1 ˆ   -0.606(0.547)  **     
Dominant effect 
2 ˆ   -0.092(0.612)  **     
MA 
1 ˆ   0.036(0.016)  *     
MW 
2 ˆ   0.043(0.022)  *     
PTD 
3 ˆ   -0.328(0.281)     
BS 
4 ˆ   -0.547(0.215)  **     
MBMI 
5 ˆ   -0.076(0.056)     
LR1 is the likelihood ratio test statistic based on hypothesis (12). The risk haplotype detected on the basis of the AIC value and LR test is indicated in boldface.  
** and * refer to significance at the 0.01 and 0.05 level, respectively.  
MA=maternal age; MW=maternal weight; PTD=number of preterm deliveries; BS=baby sex; MBMI=maternal body mass index. Nucleotide Mapping of Binary Disease Traits  Current Genomics, 2007, Vol. 8, No. 5    319 
Among the five non-genetic covariates, variables MA and 
MW are significant at the 0.05 level and variable BS is 
significant at the 0.01 level, which indicate that both 
maternal age and weight could be potential risk factors for 
LGA. Since the additive effect is negative, this indicates that 
this risk haplotype TC triggers a negative effect on LGA, 
i.e., individuals who carry composite diplotypes [TC][ C T ] 
and [ C T ][ C T ] have higher risk to develop LGA than 
individuals carrying composite diplotype [TC][TC] with 
odds ratio  3.3582 =
] ][ ]/[ ][ [ TC TC TC TC OR  and  =
] ][ ]/[ ][ [ TC TC TC TC OR  
1.6711 by holding constant for other risk factors. 
  We also calculated the odds ratio of developing LGA for 
individuals giving birth to different sex of baby. For 
example, the risk for women carrying the same composite 
diplotypes to develop LGA would be 1.73 times higher if 
they deliver baby boy compared to those who deliver baby 
girl. The risk to develop LGA for a 40-year old mother 
would be 1.7 times higher than a 25-year old mother after 
adjusting for other covariates effects. Holding constant for 
other covariates, the risk to develop LGA will be increased 
by 1.54 times for every 22 pounds weight gain. 
DISCUSSION 
  The study of common diseases can be broadly divided 
into two categories: family-based linkage studies across the 
entire genome, and population-based association studies of 
individual candidate genes [2]. While accumulative evi- 
dences have shown that linkage methods have lower power 
than population-based association methods [47,48], a more 
efficient way to study the genetic architecture of a complex 
disease is at the population level. Meanwhile, a number of 
studies have shown that haplotype-based association study is 
more powerful than single SNP analysis, especially when 
multiple disease-susceptibility variants occur within the 
same gene [11,49]. Therefore, hunting for specific DNA 
sequence patterns that are associated with the variation of a 
disease would provide efficient information in understanding 
the disease etiology. The model presented here, aimed to 
detect the association between DNA sequence variants and a 
binary disease trait, thus prides a timely tool toward better 
understanding of the genetic architecture of a complex 
binary disease trait. 
  In this article, we make an attempt to study genetic asso- 
ciation by utilizing the abundant sequence variation infor- 
mation developed by the HapMap project. The model, called 
BTN mapping, is derived on the basis of multilocus 
haplotype analysis using a finite number of htSNPs within a 
haplotype block assuming that the candidate gene is not 
imprinted. Both simulation studies and a real example show 
that our BTN mapping approach can detect haplotype 
association underlying a disease trait with high power and, 
hence displays a number of merits. 
  First, our approach can characterize the association of 
DNA sequence variants predisposing to a disease. Tradi- 
tional disease mapping approaches such as binary trait locus 
(BTL) mapping, attempt to identify loci called BTLs that are 
linked with known markers [22-24]. The specific DNA 
sequence structure for the detected loci remains unknown. 
As opposed to this traditional “indirect” approach, our model 
can directly materialize DNA sequences underlying a disease 
trait, and therefore represents a “direct” approach. It should 
be noted that our approach is limited by knowledge about the 
complete functional sequence variants information in candi- 
date regions. With the release of more SNPs by HapMap, our 
model will become more useful in search for causal variants 
throughout the whole genome. 
  Second, our approach is likelihood-based and is compu- 
tationally fast. Regular model selection criteria such as the 
AIC criterion can be applied to determine the risk haplotype 
structures on a disease trait. The developed model also 
allows for nongenetic covariates effect which might provide 
potential information in genetic association study. It has 
been shown that risk of complex diseases such as cancers 
may be determined by both genetic and environmental 
factors [50]. Incorporating the non-genetic factors should 
provide more meaningful results in association tests, and 
hence should be more preferred. 
  Third, the proposed regrouping approach could poten- 
tially increase testing power by reducing the degree of 
freedom for an association test. In general, there are two 
ways to increase the power of an association test: developing 
appropriate statistical forms for an association test or reduce 
the degrees of freedom [51]. A common limitation for 
existing haplotype-based analyses is that the test statistic 
often involves a large number of degrees of freedom. When 
large number of SNP markers are involved to construct 
haplotypes, the test could suffer from severe power loss as 
the number of degrees of freedom could be large. Through 
regrouping haplotypes, the BTM mapping approach has 
better control of the degrees of freedom because the number 
of degrees of freedom for an association test remain the same 
regardless of the number of SNPs fitted in the model. Our 
simulation studies confirmed that even for small sample size 
(< 200), when balanced sampling scheme is maintained, one 
can still obtain appropriate power. 
  Finally, the model is robust and flexible to different 
genetic and experimental settings. The results from simula- 
tion studies indicate that the association between haplotype 
and disease phenotype can be well detected under different 
gene action modes with modest sample size. It is worthy to 
note that the proportion of cases shows a great impact on 
testing power and parameter estimation by various simula- 
tions. Results indicate that a nearly balanced sampling 
design provides optimal power and low estimation biases, 
especially for small sample size. Therefore, a balanced case-
control design should always be preferred when recruiting 
samples in a case-control study. 
  The effect of allele frequencies on testing power and 
parameter estimation is also investigated (data not shown). 
Our results indicate that testing power is not affected by 
allele frequency as long as the proportion of individuals 
carry double risk haplotypes is not terribly small. However, 
we do observe inflated variances for the genetic parameters 
when sample size or allele frequency is small, which might 
be due to multicollinearity among the genetic covariates 320    Current Genomics, 2007, Vol. 8, No. 5  Cui et al. 
given the categorical nature of variables [15]. One possible 
solution is to apply a penalized regression model in which 
the log-likelihood function is penalized by a penalty term. 
Possible choices for the penalty term are Lasso type penalty 
[52] or ridge penalty [53]. When the likelihood function is 
penalized, however, the usual likelihood ratio test can not be 
applied. Efficient and robust model selection approaches 
need to be developed to solve this problem. 
  Our model is developed based on tag SNPs selected 
within a haplotype block. The purpose of using htSNPs is to 
control the number of SNPs used to construct a haplotype, 
which in turn, minimizes the computation burden for hapl- 
otype construction using EM algorithm. We may lose poten- 
tial information when the efficiency of tag SNP selection is 
low. With more and more studies focused on tag SNP 
selection, more robust tagging approaches will improve our 
mapping efficiency. It should also be noted that the assump- 
tion by using tag SNPs can be relaxed in which all SNPs 
identified within a haplotype block can be used for analysis, 
especially when the SNPs size within a block is limited. 
However, corrections for multiple testings are necessary 
when the number of tested blocks are large. 
  Our mapping approach considers binary disease traits and 
is a generalization of the model proposed by Liu et al. [19] 
which considers continuous disease traits. The specific utility 
of our model to a real example from a genetic association 
study leads to the successful detection of BTNs genotyped 
within the APOC3 candidate gene associated with LGA. 
Although our simulation studies and the example were 
illustrated based on the 2-SNP and 3-SNP models, our BTN 
mapping model has been developed to allow for the 
detection of BTN structures involving any number of SNPs. 
The model can also be easily extended to model the 
interaction between genetic factors and environments. It is 
also possible that haplotypes in one block interact with 
haplotypes in other blocks. A further extension of the model 
can be applied to model the effects of BTN-BTN interactions 
on a disease trait. 
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APPENDIX 
EM ALGORITHM FOR ESTIMATING THE PARAMETERS 
The EM algorithm for the 2-SNP model is detailed here, while the EM algorithm for theR -SNP ( 3  R ) model is similar and 
hence is omitted. 
Let  1 y  be the response vector containing the disease status for individual i ( . , 1, = n i   with  12/12 = . n n n  ), 
0 y  be the response 
vector for individual i ( 12/12 , 1, = n i  ) who carries genotype 12/12. Let  2 X  be a matrix corresponding to response vector  1 y  
with the first column being all ones, the second and third column being the elements of  1 i x  and 
2 i x  defined in Equation (4) and 
(5) for individual i respectively and the rest columns containing all the non-genetic covariates. Denote  1 X  a matrix with its 
first and third column being ones, second column being zeros, and similarly denote 
0 X  a matrix with first column being ones, 
second column being negative ones, third column being zeros, and the rest columns being the non-genetic covariates 
corresponding to individuals with genotype 12/12. Therefore, the dimension of  2 X  is  3) ( . +  p n , and the dimension of  1 X  
and 
0 X  is  3) ( 12/12 +  p n  where  p  is the number of non-genetic covariates. 
Let  i c  be the diplotype of the BTNs with observed genotype 12/12 ( 1 = i c  if diplotype [11][22] and = 0 if diplotype [12][12]). 
Since  i c  is unobservable, it is treated as missing data. Define the following three logistic regression functions  
) | 1 = ( = 2 1 2 i i i X y   ,  ) | 1 = ( = 1 0 1 i i i X y    and  ) | 1 = ( = 0 0 0 i i i X y    
where
i y0 and
i y1 are the observations corresponding to double heterozygous and other genotypes, respectively. Then, the 
complete data log-likelihood function is given by  
 
n
c    () =
i=1
n1
log[2i
y1i (12i)
1y1i ]
           +
i=1
n0
 ci log[1i
y0i (11i)
1y0i ]+ (1 ci)log[0i
y0i (10i)
1y0i ] {}
         = 
i=1
n1
 1+ exp(
j=0
p
jx2ij)


	
	






+
i=1
n1
y1i
j=0
p
jx2ij
           +
i=1
n0
 ci log[1i
y0i (11i)
1y0i ]+ (1 ci)log[0i
y0i (10i)
1y0i ] {}
 Nucleotide Mapping of Binary Disease Traits  Current Genomics, 2007, Vol. 8, No. 5    321 
Thus, in the E-step of the (t )th EM iteration, we only need to calculate  
 
i
(t) = E[ci | y0i,X1i,X0i,,
(t)]=P(ci =1|y0i,X1i,X0i,,
(t))
       =
[1i
(t)]
y0i[(11i
(t))]
1y0i
[1i
(t)]
y0i[(11i
(t))]
1y0i + (1)[0i
(t)]
y0i[(10i
(t))]
1y0i
              (A1) 
Replace the missing value  i c  by 
) (t
i   in the log-likelihood function with the complete data and then in the M-step, we 
maximize  
Q
(t) = 
i=1
n1
[1+ exp(
j=0
p
jx2ij)]+
i=1
n1
y1i
j=0
p
jx2ij
         +
i=1
n0
 i
(t) log[1i
y0i (11i)
1y0i ]+ (1i
(t))log[0i
y0i (10i)
1y0i ] {}
 
with respect to . To do so, we can use the Newton-Raphson iteration method which needs the first and the second partial 
derivatives given below.  
)] ( ) ( [ = 0 0
) (
0 1 0
) (
2 1
0
1 =
2 1
1
1 =
2 2
1
1 =
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i i
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i ij i i
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n
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t
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The Hessian matrix at the ( ) t th iteration is given by 
k j
t
t Q
H
  

) ( 2
) ( =  which leads to the updated parameters  at the 
1) ( + t th iteration 

(t+1) = 
(t) – [H
(t)]
–1 u'      ( A 2 )  
Where u is a vector of first derivative of 
) (t Q  with respect to  j  . The EM algorithm is repeated between Equation (A1) and 
(A2) until certain convergence criteria is satisfied. One of the by-product of using Newton-Raphson method is that we can 
easily obtain the standard errors of the estimated parameters through the Hessian matrix. 
 
REFERENCES 
[1]  The International HapMap Consortium. The International HapMap 
Project. Nature 2003, 426: 789-794.  
[2]  The International HapMap Consortium. The haplotype map of the 
human genome. Nature 2005, 437: 1299-1320.  
[3]  Risch, N., Merikangas, K. The future of genetic studies of complex 
human diseases. Science 1996, 273: 1516-1517.  
[4]  Olson, J.M., Wijsman, E.M. Design and sample size considerations 
in the detection of linkage disequilibrium with a marker locus. Am. 
J. Hum. Genet. 1994, 55: 574-580. 
[5]  Strittmatter, W.J., Roses, A.D. Apolipoprotein E and Alzheimer 
Disease. Proc. Natl. Acad. Sci. USA 1995, 92: 4725-4727. 
[6]  Stram, S.O., Pearce, C.L., Bretsky, P., Freedman, M., Hirschhorn, 
J.N., Altshuler, D., Kolonel, L.N., Henderson, B.E., Thomas, D.C. 
Modeling and E-M estimation of haplotype-specific relative risks 
from genotype data for a case-control study of unrelated 
individuals. Hum. Hered. 2003, 55: 179-190. 
[7]  Akey, J., Jin, L., Xiong, M. Haplotypes vs. single makrer linkage 
disequilibrium tests: what do we gain? Eur. J. Hum. Genet. 2001, 
9: 291-300. 
[8]  Clark, A.G. The role of haplotypes in candidate gene studies. 
Genet. Epidemiol. 2004, 27: 321-333. 
[9]  Schaid, D.J. Evaluating associations of haplotypes with traits. 
Genet. Epidemiol. 2004, 27: 348-364. 
[10]  Schaid, D.J., Rowland, C.M., Tines, D.E., Jacobson, R.M., Poland, 
G.A. Score tests for association between traits and haplotypes when 
linkage phase is ambiguous. Am. J. Hum. Genet. 2002, 70: 425-
434. 
[11]  Stephens, M., Smith, N.J., Donnelly, P. A new statistical method 
for haplotype reconstruction from population data. Am. J. Hum. 
Genet. 2001, 68: 978-989. 
[12]  Excoffier, L., Slatkin, M. Maximum-likelihood estimation of 
molecular haplotype frequencies in a diploid population. Mol. Biol. 
Evol. 1995, 12: 921–927. 
[13]  Zhao, J.H., Curtis, D., Sham, P.C. Model-free analysis and 
permutation tests for allelic association. Hum. Hered.  2000,  50: 
133-139. 
[14]  Epstein, M.P., Satten, G.A. Inference on haplotype effects in case-
control studies using unphased genotype data. Am. J. Hum. Genet. 
2003, 73: 1316-1329. 
[15]  Lake, S.L., Lyon, H., Tantisira, K., Silverman, E.K., Weiss, S.T., 
Laird, N.M., Schaid, D.J. Estimation and tests of haplotype-
environment interaction when linkage phase is ambiguous. Hum. 
Hered. 2003, 55: 56-65. 
[16]  Tan, Q.H., Christiansen, L., Christensen, K., Bathum, L., Li, S.X., 
Zhao, J.H., Kruse, T.A. Haplotype association analysis of human 
disease traits using genotype data of unrelated individuals. Genet. 
Res. 2005, 86: 223-231. 
[17]  Spinka, C., Carroll, R.J., Chatterjee, N. Analysis of case-control 
studies of genetic and environmental factors with missing genetic 
information and haplotype-phase ambiguity. Genet. Epidemiol. 
2005, 29: 649-659. 322    Current Genomics, 2007, Vol. 8, No. 5  Cui et al. 
[18]  Zaykin, D.V., Westfall, P.H., Young, S.S., Karnoub, M.A., 
Wagner, M.J., Ehm, M.G. Testing association of statistically 
inferred haplotypes with discrete and continuous traits in samples 
of unrelated individuals. Hum. Hered. 2002, 53: 79-91. 
[19]  Liu, T., Johnson, J.A., Casella, G., Wu, R.L. Sequencing complex 
diseases with HapMap. Genetics 2004, 168: 503-511. 
[20]  Patil, N., Berno, A.J., Hinds, D.A., Barrett, W.A., Doshi, J.M., 
Hacker, C.R., Kautzer, C.R., Lee, D.H., Marjoribanks, C., 
McDonough, D.P., Nguyen, B.T., Norris, M.C., Sheehan, J.B., 
Shen, N., Stern, D., Stokowski, R.P., Thomas, D.J., Trulson, M.O., 
Vyas, K.R., Frazer, K.A., Fodor, S.P., Cox, D.R. Blocks of limited 
haplotype diversity revealed by high-resolution scanning of human 
chromosome 21. Science 2001, 294: 1719-1723. 
[21]  Gabriel, S.B., Schaffner, S.F., Nguyen, H., Moore, J.M., Roy, J., 
Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, 
M., Liu-Cordero, S.N., Rotimi, C., Adeyemo, A., Cooper, R., 
Ward, R., Lander, E.S., Daly, M.J., Altshuler, D. The structure of 
haplotype blocks in the human genome. Science 2002, 296: 2225-
2229. 
[22]  McIntyre, L., Coffman, C., Doerge, R. Detection and location of 
single binary trait loci in experimental populations. Genet. Res. 
2001, 78: 79-92. 
[23]  Xu, S., Atchley, W.R. Mapping Quantitative Trait Loci for 
Complex Binary Diseases Using Line Crosses. Genetics 1996, 143: 
1417-1424. 
[24]  Deng, W., Chen, H., Li, Z.H. A Logistic Regression Mixture 
Model for Interval Mapping of Genetic Trait Loci Affecting Binary 
Phenotypes. Genetics 2005, 172: 1349-1358. 
[25]  Dawson, E., Abecasis, G.R., Bumpstead, S., Chen, Y., Hunt, S., 
Beare, D.M., Pabial, J., Dibling, T., Tinsley, E., Kirby, S., Carter, 
D., Papaspyridonos, M., Livingstone, S., Ganske, R., Lohmussaar, 
E., Zernant, J., Tonisson, N., Remm, M., Magi, R., Puurand, T., 
Vilo, J., Kurg, A., Rice, K., Deloukas, P., Mott, R., Metspalu, A., 
Bentley, D.R., Cardon, L.R., Dunham, I. A first-generation linkage 
disequilibrium map of human chromosome 22. Nature 2002, 418: 
544-548. 
[26]  Zhang, K., Deng, M.H., Chen, T., Waterman, M.S., Sun, F.Z. A 
dynamic programming algorithm for haplotype block partitioning. 
Proc. Natl. Acad. Sci. USA 2002, 99: 7335-7339. 
[27]  Ke, K., Cardon, L.R. Efficient selective screening of haplotype tag 
SNPs. Bioinformatics 2003, 19: 287-288. 
[28]  Greenspan, G., Geiger, D. Model-based inference of haplotype 
block variation. Proceedings of the Seventh International 
Conference on Research in Computational Molecular Biology 
2003; pp.131-137. 
[29]  Bonney, G.E. Regressive logistic models for familial disease and 
other binary traits. Biometrics 1986, 42: 611-625. 
[30]  Hosmer, D.W., Lemeshow, S. Applied Logistic Regression. New 
York: John Wiley & Sons 1989. 
[31]  Lynch, M., Walsh, B. Genetics and Analysis of Quantitative Traits. 
1998, Sinauer, Sunderland, MA. 
[32]  Dempster, A.P., Laird, N.M., Rubin, D.B. Maximum likelihood 
from incomplete data via EM algorithm. J. Roy. Stat. Soc. Ser. B 
1977, 9: 1-38. 
[33] Agresti,  A.  Categorical data analysis. New York: Wiley-Liss   
2002. 
[34]  Cui, Y.H., Kim, D.-Y. On the asymptotic distribution of likelihood 
ratio test in nucleotide mapping of complex diseases. In 
preparation. 
[35]  Akaike, H. A New Look at the Statistical Model Identification. 
IEEE Transactions on Automatic Control 1974, AC-19: 716-723. 
[36]  Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., Golani, I. 
Controlling the false discovery rate in behavior genetics research. 
Behav. Brain Res. 2001, 125: 279-284. 
[37]  Lou, X.-Y., Casella, G., Littell, R.C., Yang, M.C.K., Wu, R.L. A 
haplotype-based algorithm for multilocus linkage disequilibrium 
mapping of quantitative trait loci with epistasis in natural 
populations. Genetics 2003, 163: 1533-1548. 
[38]  Spellacy, W.N., Miller, S., Winegar, A., Peterson, P.Q. 
Macrosomia-maternal characteristics and infant complications. 
Obstet. Genycol. 1985, 66: 158-161. 
[39]  Whitaker, R.C., Dietz, W.H. Role of the prenatal environment in 
the development of obesity. J. Pediatr. 1998, 132: 768-776. 
[40]  Dietz, W.H. Overweight in childhood and adolescence. N. Engl. J. 
Med. 2004, 350: 855-857. 
[41]  Meshari, A.A., De Silva S., Rahman, I. Fetal macrosomia-maternal 
risks and fetal outcome. Int. J. Genecol. Obstet. 1990, 32: 215-222. 
[42]  Lazer, S., Biale, Y., Mazor, M., Lewenthal, H., Inslev, V. Compli- 
cations associated with the macrosomic fetus. J. Reprod. Med. 
1986, 31: 501-505. 
[43]  Meeuwise, G., Olausson, P.O. Increased birth weights in the 
Nordic countries, A growing proportion of neonates weight more 
than four kilos [in Swedish]. Lakartidningen 1998, 95: 5488-5492. 
[44]  Kramer, M.S., Morin, I., Yang, H., Platt, R.W., Usher, R., 
McNamara, H., Joseph, K.S., Wen, S.W. Why are babies getting 
bigger? Temporal trends in fetal growth and its determinants. J. 
Pediatr. 2002, 141: 538-542. 
[45]  Hao, K., Wang, X., Niu, T., Xu, X., Li, A., Chang, W., Wang, L., 
Li, G., Laird, N., Xu, X. A candidate gene association study on 
preterm delivery: application of high-throughput genotyping 
technology and advanced statistical methods. Hum. Mol. Genet. 
2004, 13: 683-691. 
[46]  Barrett, J.C., Fry, B., Maller, J., Daly, M.J. Haploview: analysis 
and visualization of LD and haplotype maps. Bioinformatics 2005, 
21: 263-265. 
[47]  Risch, N. Searching for genetic determinants in the new 
millennium. Nature 2000, 405: 847-856 
[48]  Botstein, D., Risch, N. Discovering genotypes underlying human 
phenotypes: past successes for mendelian disease, future 
approaches for complex disease. Nat. Genet. 2003, 33 (suppl): 228-
237. 
[49]  Morris, R.W., Kaplan, N.L. On the advantage of haplotype analysis 
in the presence of multiple disease susceptibility alleles. Genet. 
Epidemiol. 2002, 23: 221-233. 
[50]  Greenwald, P. Cancer risk factors for selecting cohorts for large-
scale chemoprevention trials. J. Cell. Biochem. 1996, 25 (Suppl): 
29-36. 
[51]  Zhao, J., Boerwinkle, E., Xiong, M. An entropy-based statistic for 
genomewide association studies. Am. J. Hum. Genet. 2005, 77: 27-
40. 
[52]  Tibshirani, R. Regression shrinkage and selection via the lasso. J. 
Royal. Stat. Soc. B 1996, 58: 267-288. 
[53]  Hoerl, A.E., Kennard, R.W. Ridge regression: Biased estimation 
for nonorthogonal problems. Technometrics 1970, 12: 55-67. 
 
   
 